Skip to main content
Erschienen in: Archives of Osteoporosis 1/2018

01.12.2018 | Review Article

Osteoporosis in postmenopausal women in this decade: a bibliometric assessment of current research and future hotspots

verfasst von: Yuanyu Qiu, Wu Yang, Qijin Wang, Sijia Yan, Bo Li, Xiao Zhai

Erschienen in: Archives of Osteoporosis | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Summary

Postmenopausal osteoporosis (PMOP) has already become a major public health problem. However, there was no bibliometric analysis estimating the evolutionary process of PMOP research.

Purpose

This study aimed to assess its scientific activity.

Methods

Publications on PMOP were retrieved from Science Citation Index-Expanded (SCI-E) of the Web of Science (WoS) from 2008 to 2018. VOSviewer software was used for data mining and visualization. The quantity of papers, number of citations, citation frequency per year, and H-index were assessed and compared among different countries, institutes, and researchers.

Results

A total of 11,142 papers were included and were cited 184,416 times. The USA contributed the most papers (3162), the most citations (83,270 times), and the highest H-index (115). Canada ranked first for the number of papers per million populations and per trillion GDP. Seven of the top ten funding agencies were industries. The key words were stratified into four clusters: cluster 1 (“basic research”), cluster 2 (“diagnosis”), cluster 3 (“treatment”), and cluster 4 (“others”). Average appearing years (AAY) of key words in cluster 1 were the largest compared to those in clusters 2 and 3. For hotspots, “miRNA” showed a relatively latest AAY of 2017.63, followed by “abaloparatide” and “adipokine”.

Conclusion

We concluded that the USA and Europe were the most productive regions on PMOP, with a high prevalence of articles supported by pharmaceutical companies. Key word focus gradually shifted from “diagnosis” to “treatment” and then to precision medicine orientated “basic research”. It is recommended to pay attention to potential research hotspots, such as “miRNA,” “abaloparatide,” and “adipokine”.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Kanis JA, EV MC, Johansson H, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, Osteoarthritis, the Committee of Scientific Advisors of the International Osteoporosis F (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57CrossRef Kanis JA, EV MC, Johansson H, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, Osteoarthritis, the Committee of Scientific Advisors of the International Osteoporosis F (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57CrossRef
2.
Zurück zum Zitat Black DM, Rosen CJ (2016) Clinical Practice Postmenopausal Osteoporosis. N Engl J Med 374:254–262CrossRef Black DM, Rosen CJ (2016) Clinical Practice Postmenopausal Osteoporosis. N Engl J Med 374:254–262CrossRef
3.
Zurück zum Zitat Imai T, Tanaka S, Kawakami K, Miyazaki T, Hagino H, Shiraki M, Group ATR (2017) Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial. Osteoporos Int 28:1893–1901CrossRef Imai T, Tanaka S, Kawakami K, Miyazaki T, Hagino H, Shiraki M, Group ATR (2017) Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial. Osteoporos Int 28:1893–1901CrossRef
4.
Zurück zum Zitat Biglu MH, Ghavami M, Biglu S (2014) Authorship, institutional and citation metrics for publications on postmenopausal osteoporosis. Osteoporos Int 25:1337–1343CrossRef Biglu MH, Ghavami M, Biglu S (2014) Authorship, institutional and citation metrics for publications on postmenopausal osteoporosis. Osteoporos Int 25:1337–1343CrossRef
5.
Zurück zum Zitat Chen X, Zhi X, Cao L, Weng W, Pan P, Hu H, Liu C, Zhao Q, Zhou Q, Cui J, Su J (2017) Matrine derivate MASM uncovers a novel function for ribosomal protein S5 in osteoclastogenesis and postmenopausal osteoporosis. Cell Death Dis 8:e3037CrossRef Chen X, Zhi X, Cao L, Weng W, Pan P, Hu H, Liu C, Zhao Q, Zhou Q, Cui J, Su J (2017) Matrine derivate MASM uncovers a novel function for ribosomal protein S5 in osteoclastogenesis and postmenopausal osteoporosis. Cell Death Dis 8:e3037CrossRef
6.
Zurück zum Zitat Si L, Winzenberg TM, Chen M, Jiang Q, Neil A, Palmer AJ (2016) Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study. Osteoporos Int 27:2259–2269CrossRef Si L, Winzenberg TM, Chen M, Jiang Q, Neil A, Palmer AJ (2016) Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study. Osteoporos Int 27:2259–2269CrossRef
7.
Zurück zum Zitat Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R (2016) Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int 27:21–31CrossRef Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R (2016) Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int 27:21–31CrossRef
8.
Zurück zum Zitat Glanville J, Kendrick T, McNally R, Campbell J, Hobbs FD (2011) Research output on primary care in Australia, Canada, Germany, the Netherlands, the United Kingdom, and the United States: bibliometric analysis. Bmj 342:d1028CrossRef Glanville J, Kendrick T, McNally R, Campbell J, Hobbs FD (2011) Research output on primary care in Australia, Canada, Germany, the Netherlands, the United Kingdom, and the United States: bibliometric analysis. Bmj 342:d1028CrossRef
9.
Zurück zum Zitat Bornmann L, Leydesdorff L (2014) Scientometrics in a changing research landscape: bibliometrics has become an integral part of research quality evaluation and has been changing the practice of research. EMBO Rep 15:1228–1232CrossRef Bornmann L, Leydesdorff L (2014) Scientometrics in a changing research landscape: bibliometrics has become an integral part of research quality evaluation and has been changing the practice of research. EMBO Rep 15:1228–1232CrossRef
10.
Zurück zum Zitat Avcu G, Sahbudak Bal Z, Duyu M, Akkus E, Karapinar B, Vardar F (2015) Thanks to trauma: a delayed diagnosis of Pott disease. Pediatr Emerg Care 31:e17–e18CrossRef Avcu G, Sahbudak Bal Z, Duyu M, Akkus E, Karapinar B, Vardar F (2015) Thanks to trauma: a delayed diagnosis of Pott disease. Pediatr Emerg Care 31:e17–e18CrossRef
11.
Zurück zum Zitat Zhao J, Yu G, Cai M, Lei X, Yang Y, Wang Q, Zhai X (2018) Bibliometric analysis of global scientific activity on umbilical cord mesenchymal stem cells: a swiftly expanding and shifting focus. Stem Cell Res Ther 9:32CrossRef Zhao J, Yu G, Cai M, Lei X, Yang Y, Wang Q, Zhai X (2018) Bibliometric analysis of global scientific activity on umbilical cord mesenchymal stem cells: a swiftly expanding and shifting focus. Stem Cell Res Ther 9:32CrossRef
12.
Zurück zum Zitat Gao Y, Wang Y, Zhai X, He Y, Chen R, Zhou J, Li M, Wang Q (2017) Publication trends of research on diabetes mellitus and T cells (1997-2016): a 20-year bibliometric study. PLoS One 12:e0184869CrossRef Gao Y, Wang Y, Zhai X, He Y, Chen R, Zhou J, Li M, Wang Q (2017) Publication trends of research on diabetes mellitus and T cells (1997-2016): a 20-year bibliometric study. PLoS One 12:e0184869CrossRef
13.
Zurück zum Zitat Yiran W, Qijin W, Xianzhao W, et al. (2017) Global scientific trends on exosome research during 2007-2016: a bibliometric analysis. Oncotarget Yiran W, Qijin W, Xianzhao W, et al. (2017) Global scientific trends on exosome research during 2007-2016: a bibliometric analysis. Oncotarget
14.
Zurück zum Zitat Wang Y, Wang Q, Zhu R, Yang C, Chen Z, Bai Y, Li M, Zhai X (2016) Trends of spinal tuberculosis research (1994-2015): a bibliometric study. Medicine 95:e4923CrossRef Wang Y, Wang Q, Zhu R, Yang C, Chen Z, Bai Y, Li M, Zhai X (2016) Trends of spinal tuberculosis research (1994-2015): a bibliometric study. Medicine 95:e4923CrossRef
15.
Zurück zum Zitat Sweileh WM (2017) Bibliometric analysis of literature on toxic epidermal necrolysis and Stevens-Johnson syndrome: 1940 - 2015. Orphanet J Rare Dis 12:14CrossRef Sweileh WM (2017) Bibliometric analysis of literature on toxic epidermal necrolysis and Stevens-Johnson syndrome: 1940 - 2015. Orphanet J Rare Dis 12:14CrossRef
16.
Zurück zum Zitat Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G (2009) Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A 106:8368–8373CrossRef Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G (2009) Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A 106:8368–8373CrossRef
17.
Zurück zum Zitat Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Pathology 41:40–47CrossRef Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Pathology 41:40–47CrossRef
18.
Zurück zum Zitat Synnestvedt MB, Chen C, Holmes JH (2005) CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annual Symposium proceedings / AMIA Symposium AMIA Symposium 724–728 Synnestvedt MB, Chen C, Holmes JH (2005) CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annual Symposium proceedings / AMIA Symposium AMIA Symposium 724–728
19.
Zurück zum Zitat Khalil GM, Gotway Crawford CA (2015) A bibliometric analysis of U.S.-based research on the behavioral risk factor surveillance system. Am J Prev Med 48:50–57CrossRef Khalil GM, Gotway Crawford CA (2015) A bibliometric analysis of U.S.-based research on the behavioral risk factor surveillance system. Am J Prev Med 48:50–57CrossRef
20.
Zurück zum Zitat Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRef Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRef
21.
Zurück zum Zitat Kanis JA, Cooper C, Rizzoli R, Reginster JY (2018) Review of the guideline of the American College of Physicians on the treatment of osteoporosis. Osteoporos Int 29:1505–1510CrossRef Kanis JA, Cooper C, Rizzoli R, Reginster JY (2018) Review of the guideline of the American College of Physicians on the treatment of osteoporosis. Osteoporos Int 29:1505–1510CrossRef
22.
Zurück zum Zitat Hiligsmann M, Evers SM, Ben Sedrine W, Kanis JA, Ramaekers B, Reginster JY, Silverman S, Wyers CE, Boonen A (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. PharmacoEconomics 33:205–224CrossRef Hiligsmann M, Evers SM, Ben Sedrine W, Kanis JA, Ramaekers B, Reginster JY, Silverman S, Wyers CE, Boonen A (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. PharmacoEconomics 33:205–224CrossRef
23.
Zurück zum Zitat Reginster JY, Hattersley G, Williams GC, Hu MY, Fitzpatrick LA, Lewiecki EM (2018) Abaloparatide is an effective treatment option for postmenopausal osteoporosis: review of the number needed to treat compared with Teriparatide. Calcif Tissue Int 103:540–545CrossRef Reginster JY, Hattersley G, Williams GC, Hu MY, Fitzpatrick LA, Lewiecki EM (2018) Abaloparatide is an effective treatment option for postmenopausal osteoporosis: review of the number needed to treat compared with Teriparatide. Calcif Tissue Int 103:540–545CrossRef
24.
Zurück zum Zitat Tijssen RJ, Winnink J (2016) Twenty-first century macro-trends in the institutional fabric of science: bibliometric monitoring and analysis. Scientometrics 109:2181–2194CrossRef Tijssen RJ, Winnink J (2016) Twenty-first century macro-trends in the institutional fabric of science: bibliometric monitoring and analysis. Scientometrics 109:2181–2194CrossRef
25.
Zurück zum Zitat Jin Y, Cui Z, Li X, Jin X, Peng J (2017) Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer. Oncotarget 8:26090–26099PubMedPubMedCentral Jin Y, Cui Z, Li X, Jin X, Peng J (2017) Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer. Oncotarget 8:26090–26099PubMedPubMedCentral
26.
Zurück zum Zitat Cerreta F, Eichler HG, Rasi G (2012) Drug policy for an aging population--the European medicines Agency's geriatric medicines strategy. N Engl J Med 367:1972–1974CrossRef Cerreta F, Eichler HG, Rasi G (2012) Drug policy for an aging population--the European medicines Agency's geriatric medicines strategy. N Engl J Med 367:1972–1974CrossRef
27.
Zurück zum Zitat Zhang L, Pang Y, Shi Y, Xu M, Xu X, Zhang J, Ji L, Zhao D (2015) Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Menopause 22:1021–1025CrossRef Zhang L, Pang Y, Shi Y, Xu M, Xu X, Zhang J, Ji L, Zhao D (2015) Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Menopause 22:1021–1025CrossRef
28.
Zurück zum Zitat Kim K, Svedbom A, Luo X, Sutradhar S, Kanis JA (2014) Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. Osteoporos Int 25:325–337CrossRef Kim K, Svedbom A, Luo X, Sutradhar S, Kanis JA (2014) Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. Osteoporos Int 25:325–337CrossRef
29.
Zurück zum Zitat Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E, Krieg MA, Man Z, Mellström D, Radominski SC, Reginster JY, Resch H, Ivorra JAR, Roux C, Vittinghoff E, Austin M, Daizadeh N, Bradley MN, Grauer A, Cummings SR, Bone HG (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694–701CrossRef Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E, Krieg MA, Man Z, Mellström D, Radominski SC, Reginster JY, Resch H, Ivorra JAR, Roux C, Vittinghoff E, Austin M, Daizadeh N, Bradley MN, Grauer A, Cummings SR, Bone HG (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694–701CrossRef
30.
Zurück zum Zitat Papapoulos S, Lippuner K, Roux C, Lin CJF, Kendler DL, Lewiecki EM, Brandi ML, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int 26:2773–2783CrossRef Papapoulos S, Lippuner K, Roux C, Lin CJF, Kendler DL, Lewiecki EM, Brandi ML, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int 26:2773–2783CrossRef
31.
Zurück zum Zitat Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543CrossRef Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543CrossRef
32.
Zurück zum Zitat Liu Y, Cao Y, Zhang S, Zhang W, Zhang B, Tang Q, Li Z, Wu J (2018) Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials. Climacteric 21:189–195CrossRef Liu Y, Cao Y, Zhang S, Zhang W, Zhang B, Tang Q, Li Z, Wu J (2018) Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials. Climacteric 21:189–195CrossRef
33.
Zurück zum Zitat de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine AB, Codreanu C, Kelepouris N, Brown JP (2011) Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 22:567–576CrossRef de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine AB, Codreanu C, Kelepouris N, Brown JP (2011) Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 22:567–576CrossRef
34.
Zurück zum Zitat Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjaerg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD, Bazedoxifene Study G (2012) Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 23:351–363CrossRef Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjaerg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD, Bazedoxifene Study G (2012) Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 23:351–363CrossRef
35.
Zurück zum Zitat Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382:50–56CrossRef Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382:50–56CrossRef
36.
Zurück zum Zitat Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 26:503–511CrossRef Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 26:503–511CrossRef
37.
Zurück zum Zitat Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T, EUROFORS Investigators (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23:1591–1600CrossRef Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T, EUROFORS Investigators (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23:1591–1600CrossRef
38.
Zurück zum Zitat Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, Smith SY, Hattersley G (2018) Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporos Int 29:685–697CrossRef Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, Smith SY, Hattersley G (2018) Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporos Int 29:685–697CrossRef
39.
Zurück zum Zitat Jin D, Wu X, Yu H, Jiang L, Zhou P, Yao X, Meng J, Wang L, Zhang M, Zhang Y (2018) Systematic analysis of lncRNAs, mRNAs, circRNAs and miRNAs in patients with postmenopausal osteoporosis. Am J Transl Res 10:1498–1510PubMedPubMedCentral Jin D, Wu X, Yu H, Jiang L, Zhou P, Yao X, Meng J, Wang L, Zhang M, Zhang Y (2018) Systematic analysis of lncRNAs, mRNAs, circRNAs and miRNAs in patients with postmenopausal osteoporosis. Am J Transl Res 10:1498–1510PubMedPubMedCentral
40.
Zurück zum Zitat Li H, Wang Z, Fu Q, Zhang J (2014) Plasma miRNA levels correlate with sensitivity to bone mineral density in postmenopausal osteoporosis patients. Biomarkers 19:553–556CrossRef Li H, Wang Z, Fu Q, Zhang J (2014) Plasma miRNA levels correlate with sensitivity to bone mineral density in postmenopausal osteoporosis patients. Biomarkers 19:553–556CrossRef
41.
Zurück zum Zitat Xiong K, Wu T, Fan Q, Chen L, Yan M (2017) Novel reduced graphene oxide/zinc silicate/calcium silicate Electroconductive biocomposite for stimulating osteoporotic bone regeneration. ACS Appl Mater Interfaces 9:44356–44368CrossRef Xiong K, Wu T, Fan Q, Chen L, Yan M (2017) Novel reduced graphene oxide/zinc silicate/calcium silicate Electroconductive biocomposite for stimulating osteoporotic bone regeneration. ACS Appl Mater Interfaces 9:44356–44368CrossRef
42.
Zurück zum Zitat Kochetkova EA, Ugai LG, Maistrovskaia YV, Nevzorova VA (2017) Adipokines: a possible contribution to vascular and bone remodeling in idiopathic pulmonary arterial hypertension. Calcif Tissue Int 100:325–331CrossRef Kochetkova EA, Ugai LG, Maistrovskaia YV, Nevzorova VA (2017) Adipokines: a possible contribution to vascular and bone remodeling in idiopathic pulmonary arterial hypertension. Calcif Tissue Int 100:325–331CrossRef
43.
Zurück zum Zitat Moradi S, Mirzaei K, Abdurahman AA, Keshavarz SA (2017) Adipokines may mediate the relationship between resting metabolic rates and bone mineral densities in obese women. Osteoporos Int 28:1619–1629CrossRef Moradi S, Mirzaei K, Abdurahman AA, Keshavarz SA (2017) Adipokines may mediate the relationship between resting metabolic rates and bone mineral densities in obese women. Osteoporos Int 28:1619–1629CrossRef
Metadaten
Titel
Osteoporosis in postmenopausal women in this decade: a bibliometric assessment of current research and future hotspots
verfasst von
Yuanyu Qiu
Wu Yang
Qijin Wang
Sijia Yan
Bo Li
Xiao Zhai
Publikationsdatum
01.12.2018
Verlag
Springer London
Erschienen in
Archives of Osteoporosis / Ausgabe 1/2018
Print ISSN: 1862-3522
Elektronische ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-018-0534-5

Weitere Artikel der Ausgabe 1/2018

Archives of Osteoporosis 1/2018 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.